Short description:
AAV capsid Gene Therapy
Drug notes:
13+ additional undisclosed programs RD ALS, Friedreich's ataxia, Parkinson's, rare neurological disease, CNS diseases, undisclosed
Long description:
Voyager Therapeutics is advancing delivery modalities for gene therapies. Many gene therapies are in development, yet delivery of the therapy is still a major limitation. AAVs are a popular choice but require high doses and have off-target effects. Voyager is using its TRACER screening platform to enhance AAV capsids’ specificity and ability to target desired cells and tissues. Voyager’s AAVs also pass the blood-brain barrier, offering the potential to cure neurological diseases. Initial non-human primate data demonstrate the selectivity of TRACER-derived capsids to target the CNS and cardiac muscle. These capsids may enable single-dose treatment for a broad spectrum of diseases.
Jobs:
Senior Director, FP&A Financial Systems and Operat... Lexington, MA|9 days ago
CONTRACTOR - Analytical Sciences Lexington, MA|16 days ago
Director, Regulatory Medical Writing Lexington, MA|79 days ago
Medical Director/Senior Medical Director Lexington, MA|93 days ago
Director/Senior Director, Chemical Biology Lexington, MA|100+ days ago
Voyager Prospects - Submit for future opportunitie... Cambridge/Lexington, MA|100+ days ago